|
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test -Pub
|
|
17
|
668
|
May 23, 2025
|
|
Quantification of Nitrite in Excipients and Chemicals: A Versatile and Highly Sensitive Method Using Headspace Gas Chromatography Coupled to Mass Spectrometry -Pub
|
|
0
|
2383
|
July 23, 2024
|
|
Metformin and nitrosation of guanidines
|
|
8
|
387
|
May 21, 2025
|
|
N-Nitroso Spinosad Impurity-A and Impurity-D
|
|
2
|
154
|
May 21, 2025
|
|
The Analytical Methods and Open Spectral database by EPA
|
|
0
|
137
|
May 20, 2025
|
|
EMA Q&A Rev. 22 (EMA/409815/2020 Rev.22)
|
|
4
|
604
|
May 20, 2025
|
|
Using the relative potency comparison approach, Powley et al have demonstrated the safety of NTTP exposures at or above levels of 1500 ng/day
|
|
2
|
341
|
May 17, 2025
|
|
How to circumvent matrix effect in confirmatory testing
|
|
7
|
514
|
May 16, 2025
|
|
👨💻 Determination of nitrite and nitrate in povidone by ion chromatography as part of nitrosamine risk assessment in excipients
|
|
5
|
625
|
May 15, 2025
|
|
Nitrate and nitrite food composition database: an update and extensive deep dive
|
|
2
|
277
|
May 14, 2025
|
|
🇲🇽 Free Lhasa México Symposia: Shaping the Future of Pharma & Regulation 🇲🇽
|
|
0
|
100
|
May 13, 2025
|
|
HESI GTTC ring trial: Concordance between Ames and rodent carcinogenicity outcomes for N-nitrosamines (NAs) with rat and hamster metabolic conditions -Pub
|
|
0
|
100
|
May 13, 2025
|
|
N-Nitrosamine impurity of heterocyclic aromatic ring
|
|
17
|
3716
|
May 13, 2025
|
|
FDA Accelerating the use of AI-Assisted Scientific Review
|
|
3
|
279
|
May 12, 2025
|
|
Total Nitrosamine Analyzer
|
|
3
|
213
|
May 12, 2025
|
|
Nitrosamine Mitigation: A Path to Regulatory Compliance
|
|
1
|
430
|
May 11, 2025
|
|
Health Canada: Nitrosamine impurities Update July 26, 2024
|
|
16
|
1508
|
May 9, 2025
|
|
Any method available for N-nitosodesmethyl cyclobenzaprine/amitryptyline
|
|
0
|
82
|
May 8, 2025
|
|
From Identification to Quantitation: A Complete Workflow for NDSRI Analysis
|
|
0
|
343
|
May 8, 2025
|
|
NitrosAMIDES - Should they be treated the same as Nitrosamines?
|
|
3
|
951
|
May 7, 2025
|
|
Understanding Aqueous Nitrosation Kinetics of 4-Substituted Piperidines To Risk Assess Pharmaceutical Processes and Products-Pub
|
|
1
|
141
|
May 6, 2025
|
|
How to set Acceptance criteria for nitrosamines impurities in FDC-FPPs
|
|
1
|
150
|
May 6, 2025
|
|
N-nitroso-Impurity C in Metamizol Drug product
|
|
16
|
1914
|
May 6, 2025
|
|
Phenyl Morpholine
|
|
4
|
226
|
May 6, 2025
|
|
Nitrosamine internal standards - what should be taken into consideration?
|
|
5
|
286
|
May 6, 2025
|
|
Interferencia de matriz para cuantificación de NDBA
|
|
0
|
66
|
May 5, 2025
|
|
📅 Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
39
|
3343
|
May 2, 2025
|
|
MDD for Metformin
|
|
4
|
235
|
May 2, 2025
|
|
:australia: TGA - Latest Update to Nitrosamine Limits
|
|
8
|
1751
|
May 2, 2025
|
|
Nitrosourea, aromatic n-nitroso copmounds
|
|
2
|
199
|
May 2, 2025
|